Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
VJHemOnc was official media partner of the NYC-Miami Myeloma MRD 2020 Virtual Meeting which took place on the 8th of October 2020 and was organized by MMRF & Memorial Sloan Kettering Cancer Center.
The meeting brought together leading experts in multiple myeloma who discussed the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussion.
Watch the meeting on-demand below!
Debates
Session 1: Should sustained MRD negativity be used to stop the treatment?
Yes: Nina Shah, UCSF and MMRC Steering Committee
No: Ajai Chari, MD, Icahn School of Medicine at Mount Sinai and MMRC Steering Committee
Session 2: Should MRD+ be used to re-initiate the treatment?
Yes: Elisabet Manasanch, MD Anderson
No: Amrita Krishnan, MD, City of Hope and MMRC Steering Committee
Session 3: Should MRD be used to guide delayed ASCT?
Continue with transplant: Noa Biran, MD, John Theurer Cancer Center
Hold off transplant: Paul Richardson, MD, DFCI
